SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies’ (Nasdaq: BIAF; BIAFW) Vice President of Diagnostics, Jennifer Rebeles, Ph.D., was part of a panel of worldwide experts that published the ...

Flow cytometry effectively detects CTCs in melanoma patients, offering a rapid, cost-effective alternative to molecular biology. CTCs are present across all melanoma stages, with a significant ...

Noninvasive diagnostic continues to gain traction in the current and expanding U.S. addressable market of $3.58 billion for pulmonary nodule management and surveillance of lung cancer survivorsFlow ...

Affinity Technologies, Inc. (BIAF) announced on Wednesday that its CyPath Lung test has surpassed sales expectations in the first quarter of 2026, recording a 146% year-over-year increase in unit ...

New test as sensitive as next-generation sequencing, and provides five-day specimen stability to support nationwide testing SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ -- Quest Diagnostics (DGX), a ...

In the relentless fight against cancer, a new technology promises to shed light on how we track and understand the spread of this disease within the body. A research team from Northeastern University ...

Detailed price information for Bioaffinity Technologies Inc (BIAF-Q) from The Globe and Mail including charting and trades.

Let's Talk Science. Let's Talk Medicine. The leading scientific social networking website and producer of educational virtual events and webinars.

Rare cancers encompass a heterogeneous group of malignancies characterized by low incidence and prevalence but, often, disproportionately high mortality ...

Flow cytometry is a key diagnostic technique in hematology that provides protein information at a single-cell level. Traditionally interpreted manually in a sequence of two-dimensional plots, ...